Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment
- PMID: 12558458
- DOI: 10.2165/00003495-200363040-00002
Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment
Abstract
Extended spectrum beta-lactamase (ESBL)-producing organisms pose unique challenges to clinical microbiologists, clinicians, infection control professionals and antibacterial-discovery scientists. ESBLs are enzymes capable of hydrolysing penicillins, broad-spectrum cephalosporins and monobactams, and are generally derived from TEM and SHV-type enzymes. ESBLs are often located on plasmids that are transferable from strain to strain and between bacterial species. Although the prevalence of ESBLs is not known, it is clearly increasing, and in many parts of the world 10-40% of strains of Escherichia coli and Klebsiella pneumoniae express ESBLs. ESBL-producing Enterobacteriaceae have been responsible for numerous outbreaks of infection throughout the world and pose challenging infection control issues. Clinical outcomes data indicate that ESBLs are clinically significant and, when detected, indicate the need for the use of appropriate antibacterial agents. Unfortunately, the laboratory detection of ESBLs can be complex and, at times, misleading. Antibacterial choice is often complicated by multi-resistance. Many ESBL-producing organisms also express AmpC beta-lactamases and may be co-transferred with plasmids mediating aminoglycoside resistance. In addition, there is an increasing association between ESBL production and fluoroquinolone resistance. Although in in vitro tests ESBLs are inhibited by beta-lactamase inhibitors such as clavulanic acid, the activity of beta-lactam/beta-lactamase inhibitor combination agents is influenced by the bacterial inoculum, dose administration regimen and specific type of ESBL present. Currently, carbapenems are regarded as the drugs of choice for treatment of infections caused by ESBL-producing organisms. Unfortunately, use of carbapenems has been associated with the emergence of carbapenem-resistant bacterial species such as Stenotrophomonas sp. or Pseudomonas sp.
Similar articles
-
Extended-spectrum beta-lactamases: a clinical update.Clin Microbiol Rev. 2005 Oct;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005. Clin Microbiol Rev. 2005. PMID: 16223952 Free PMC article. Review.
-
Extended-spectrum beta-lactamases (ESbLs): characterization, epidemiology and detection.Crit Rev Microbiol. 2004;30(1):25-32. doi: 10.1080/10408410490266429. Crit Rev Microbiol. 2004. PMID: 15116761 Review.
-
Extended-spectrum beta-lactamase-producing organisms.J Hosp Infect. 2009 Dec;73(4):345-54. doi: 10.1016/j.jhin.2009.02.021. Epub 2009 Jul 10. J Hosp Infect. 2009. PMID: 19596491 Review.
-
Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.Korean J Lab Med. 2008 Dec;28(6):401-12. doi: 10.3343/kjlm.2008.28.6.401. Korean J Lab Med. 2008. PMID: 19127103 Review.
-
Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control.J Microbiol Immunol Infect. 2006 Aug;39(4):264-77. J Microbiol Immunol Infect. 2006. PMID: 16926972 Review.
Cited by
-
Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.BMC Infect Dis. 2012 Sep 5;12:206. doi: 10.1186/1471-2334-12-206. BMC Infect Dis. 2012. PMID: 22947300 Free PMC article.
-
Extended Spectrum β-Lactamase-Producing Enterobacterales of Shrimp and Salmon Available for Purchase by Consumers in Canada-A Risk Profile Using the Codex Framework.Antibiotics (Basel). 2023 Sep 6;12(9):1412. doi: 10.3390/antibiotics12091412. Antibiotics (Basel). 2023. PMID: 37760708 Free PMC article. Review.
-
Detection of Extended Spectrum β-lactamase Production Among Uropathogens.J Lab Physicians. 2009 Jan;1(1):7-10. doi: 10.4103/0974-2727.44423. J Lab Physicians. 2009. PMID: 21938241 Free PMC article.
-
Molecular Characterization of Antibiotic Resistance Associated with TEM and CTX-M ESBL in Uropathogenic E. coli Strains Isolated from Outpatients.Iran J Pathol. 2021 Fall;16(4):386-391. doi: 10.30699/IJP.20201.521669.2556. Epub 2021 Jul 6. Iran J Pathol. 2021. PMID: 34567187 Free PMC article.
-
Antimicrobial susceptibility pattern of Shigella spp. isolated from children under 5 years of age attending tertiary care hospitals, Nepal along with first finding of ESBL-production.BMC Res Notes. 2017 Jun 5;10(1):192. doi: 10.1186/s13104-017-2512-1. BMC Res Notes. 2017. PMID: 28583187 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources